Aribio Publishes SCI-Level International Journal Article on Low-Frequency Vibroacoustic Digital Therapeutics Technology

Aribio announced on the 12th that it has published the results of its clinical research on transcranial vibroacoustic stimulation (tVAS) for improving cognitive function and psychological status in the elderly in the international academic journal Frontiers in Aging Neuroscience.

This journal is ranked in the top 25% (Q1) in the fields of neuroscience and geriatrics and is classified as an SCI-level publication. This publication signifies that Aribio's technological capabilities and research achievements have been officially recognized by the global academic community.

Unlike electrical or magnetic stimulation, tVAS is a new non-pharmacological and non-invasive approach that modulates brain neural circuits through low-frequency acoustic vibrations applied directly to the head. In the clinical trial, 20Hz and 40Hz acoustic vibrations were applied to elderly participants aged 55 to 85 over eight weeks. As a result, both groups showed significant improvement in cognitive function with a statistical confidence level exceeding 95%.

Notably, the 40Hz stimulation group demonstrated improvements in depressive symptoms and changes in brainwave activity, confirming its effects in promoting neural activation and plasticity. This suggests that it can make a substantial contribution to enhancing brain functions such as concentration and memory.

Based on these research results, the Aribio Digital Health Team developed the personal wellness product "Herzion" and launched it in domestic and international markets. The company is working to expand exports to Japan, Germany, and the Middle East, and is conducting digital therapeutics clinical trials for patients with early Alzheimer's disease and mild cognitive impairment in collaboration with Bundang Seoul National University Hospital and Chosun University Hospital. Through these efforts, Aribio plans to accelerate its entry into the brain neuromodulation therapeutics market.

The company stated, "This announcement is more than just an academic achievement; it signals the beginning of corporate value growth," adding, "Our differentiated non-pharmacological digital therapeutics technology, with its safety and accessibility, is being evaluated as a new therapeutic paradigm that can be used alongside existing antibody drugs."

Aribio is also conducting a global Phase 3 clinical trial of its oral Alzheimer's treatment AR1001, while expanding its portfolio to include digital therapeutics. The company emphasized the need to pay attention to its growth potential through a multi-pronged strategy.

The company is in the process of merging with Solux, a lighting specialist company. Upon completion of the merger, Aribio expects to secure both a stable business foundation and greater recognition in the capital market.

This content was produced with the assistance of AI translation services.